The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subcutaneous daratumumab (DARA SC) plus lenalidomide versus lenalidomide alone as maintenance therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are minimal residual disease (MRD) positive after frontline autologous stem cell transplant (ASCT): The phase 3 AURIGA study.
 
Nina Shah
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Abbvie; Indapta Therapeutics; Karyopharm Therapeutics; Oncopeptides; Precision Biosciences; Sanofi; Surface Oncology
Research Funding - Bluebird Bio; Celgene; Janssen; Nektar; poseida therapeutics; Sutro biopharma; Teneobio
 
Sharmila Patel
Employment - Janssen
 
Huiling Pei
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Ming Qi
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Maria Krevvata
Stock and Other Ownership Interests - Amicus Therapeutics (I); Amicus Therapeutics (I)
 
Thomas S. Lin
Employment - Johnson & Johnson
Stock and Other Ownership Interests - GlaxoSmithKline; Johnson & Johnson
 
Vipin Khare
Employment - Janssen